Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Identifieur interne : 001080 ( Ncbi/Curation ); précédent : 001079; suivant : 001081Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Auteurs : Ruklanthi De Alwis [Singapour] ; Shiwei Chen [Singapour] ; Esther S. Gan [Singapour] ; Eng Eong Ooi [Singapour]Source :
- EBioMedicine [ 2352-3964 ] ; 2020.
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
DOI: 10.1016/j.ebiom.2020.102768
PubMed: 32344202
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000021
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000021
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000094
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001080
Links to Exploration step
pubmed:32344202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title><author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea><wicri:noRegion>SingHealth Duke-NUS Academic Medical Centre</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea><wicri:noRegion>Duke-NUS Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea><wicri:noRegion>Duke-NUS Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name><affiliation wicri:level="4"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea><orgName type="university">Université nationale de Singapour</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32344202</idno><idno type="pmid">32344202</idno><idno type="doi">10.1016/j.ebiom.2020.102768</idno><idno type="wicri:Area/PubMed/Corpus">000021</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000021</idno><idno type="wicri:Area/PubMed/Curation">000021</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000021</idno><idno type="wicri:Area/PubMed/Checkpoint">000094</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000094</idno><idno type="wicri:Area/Ncbi/Merge">001080</idno><idno type="wicri:Area/Ncbi/Curation">001080</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title><author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea><wicri:noRegion>SingHealth Duke-NUS Academic Medical Centre</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea><wicri:noRegion>Duke-NUS Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea><wicri:noRegion>Duke-NUS Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name><affiliation wicri:level="4"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea><orgName type="university">Université nationale de Singapour</orgName></affiliation></author></analytic><series><title level="j">EBioMedicine</title><idno type="eISSN">2352-3964</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001080 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001080 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:32344202
|texte= Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:32344202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |